Glaxo and Theravance Get European Marketing Approval for Relvar Ellipta

GlaxoSmithKline (NYSE: GSK  ) and Theravance (NASDAQ: THRX  ) will soon bring their Relvar Ellipta medication to market in Europe. The companies announced in a joint press release that the European Commission (the European Union's executive branch) has granted marketing authorization for the treatment. This gives the companies license to sell it in 31 countries on the continent.

Relvar Ellipta is delivered once per day using Ellipta, a dry powder inhaler. The drug is used to treat both asthma and chronic obstructive pulmonary disease, known better as COPD. For the former affliction, the drug can be used as a regular treatment in patients 12 and older. For the latter, Relvar Ellipta can be used for symptomatic treatment of adults.

GlaxoSmithKline will receive a milestone payment of $15 million from Theravance. The payment was conditional on the commission's granting marketing authorization.

At the end of its most recently reported quarter, Theravance had nearly $600 million in cash and equivalents. 


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2733411, ~/Articles/ArticleHandler.aspx, 9/30/2014 2:05:05 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement